✦ LIBER ✦

SELECT-2 Clinical Trial Assessing the Efficacy and Saftey of Controlled-Release Interferon Alpha-2B (CR2b)+Ribavirin (RBV) Versus Pegylated Interferon Alpha-2B (Peg2b)+RBV in Treatment-NaïVE Genotype-1 (G1) Hepatitis C

✍ Scribed by Younossi, Zobair M. ;Lawitz, Eric J. ;Krastev, Zahary ;Rigney, Amy ;Tchernev, Konstantin ;Takov, Dimitar ;Ghalib, Reem H. ;Long, Walker A.

Book ID: 122135129
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 258 KB
Volume: 140
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(11)63908-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

444 SVR FOR CONTROLLED-RELEASE INTERFERO

444 SVR FOR CONTROLLED-RELEASE INTERFERON ALPHA-2B (CR2B) +RIBAVIRIN COMPARED TO PEGYLATED INTERFERON ALPHA-2B (PEG2B) +RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 (G1) HEPATITIS C: FINAL RESULTS FROM SELECT-2

✍ E. Lawitz; Z. Younossi; R. Mehra; A. Rigney; Z. Krastev; K. Tchernev; D. Takov; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 116 KB

Treatment of chronic hepatitis C in HIV

Treatment of chronic hepatitis C in HIV infected patients (PTS) with pegylated interferon alpha 2B (PEG-IFN) plus ribavirin (RBV) versus pegylated interferon alpha 2B

✍ A. Cargnel; E. Angeli; A. Mainini; A. Casella; G. Gubertini; R. Giorgi; G. Orlan 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 156 KB

272 EARLY VIRAL RESPONSE OF CONTROLLED-R

272 EARLY VIRAL RESPONSE OF CONTROLLED-RELEASE INTERFERON ALPHA2B AND RIBAVIRIN VS. PEGYLATED-INTERFERON ALPHA2B AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE1 HEPATITIS C: 12 WEEK RESULTS (SELECT-2 TRIAL)

✍ E. Lawitz; Z. Younossi; P. Mehra; A. Rigney; Z. Krastev; K. Tchernev; D. Takov; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Clinical trial: peg-interferon alfa-2b a

Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation

✍ F. LODATO; S. BERARDI; A. GRAMENZI; G. MAZZELLA; M. LENZI; M. C. MORELLI; M. R. 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB

Insulin resistance undermines the advant

Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1

✍ Eiichi Ogawa; Norihiro Furusyo; Masayuki Murata; Hiroaki Ikezaki; Takeshi Ihara; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 796 KB

58 RANDOMIZED, OPEN-LABEL, 12-WEEK COMPA

58 RANDOMIZED, OPEN-LABEL, 12-WEEK COMPARISON OF CONTROLLED-RELEASE INTERFERON ALPHA2B +RIBAVRIN VS. PEGYLATED-INTERFERON ALPHA2B +RIBAVRIN IN TREATMENT-NAIVE GENOTYPE1 HEPATITIS C: 4 WEEK RESULTS FROM 480STUDY (PANEL A)

✍ Z. Krastev; I. Kotzev; K. Tchernev; A. Rigney; D. Nikolovska; B. Vladimirov; F.A 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 93 KB